Action AMPH AMPHASTAR PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Amphastar Pharmaceuticals, Inc.

Actions

AMPH

US03209R1032

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 15/07/2024 		Varia. 5j. Varia. 1 janv.
38,76 USD +0,16 % Graphique intraday de Amphastar Pharmaceuticals, Inc. +3,72 % -37,33 %
04/06 Amphastar Pharmaceuticals, Inc. approuve la nomination de Howard Lee en tant qu'administrateur CI
03/06 Amphastar Pharmaceuticals, Inc. annonce une augmentation de son plan de rachat d'actions. CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) added to Russell 2000 Dynamic Index
Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director
Amphastar Pharmaceuticals' Board Approves $50 Million Increase to Share Buyback Plan
Amphastar Pharmaceuticals, Inc. announces an Increase in Equity Buyback.
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Sector Update: Health Care Stocks Slightly Higher Late Afternoon
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Amphastar Pharmaceuticals Gains US FDA Approval for Generic Bronchospasm Drug
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Amphastar: Q1 Earnings Snapshot
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $1.04, vs. Street Est of $0.79
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 Revenue $171.8M, vs. Street Est of $174.7M
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AMPH
  4. Actualités Amphastar Pharmaceuticals, Inc.
  5. Autres langues